The Experts below are selected from a list of 816 Experts worldwide ranked by ideXlab platform

Samir Malhotra - One of the best experts on this subject based on the ideXlab platform.

  • Review Article Terminalia arjuna in Chronic Stable Angina: Systematic Review and Meta-Analysis
    2016
    Co-Authors: Harpreet Kaur, Neelima Chadha, Samir Malhotra
    Abstract:

    Copyright © 2014 Navjot Kaur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Terminalia arjuna is a popular Indian medicinal plant with its bark been used for over centuries as cardiotonic. The bark has been found to contain several bioactive compounds including saponins and flavonoids. A number of experimental and clinical studies have been conducted to explore therapeutic potential of Terminalia arjuna in cardiovascular ailments specially in patients of coronary heart disease. A number of narrative reviews have been done but no systematic review has been conducted to date. Objective. To systematically review and conduct a meta-analysis on the available literature evaluating the efficacy of Terminalia arjuna in patients of chronic stable angina. Study selection. We included randomised, pseudo-randomized and before-after comparative studies which compared Terminalia arjuna/commercial preparation of Terminalia arjunawith current standard/ conventional treatment regimens in patients with chronic stable angina. Findings. Studies were found to be of poor methodological design. We found no significant difference in the Terminalia arjuna group as compared to control arm in the outcomes for which we were able to pool data and undertake meta-analysis. Conclusions. Currently, the evidence is insufficient to draw any definit

  • Terminalia arjuna in Chronic Stable Angina: Systematic Review and Meta-Analysis
    Cardiology Research and Practice, 2014
    Co-Authors: Navjot Kaur, Nusrat Shafiq, H. Negi, Avaneesh Pandey, Srinivas Reddy, Harpreet Kaur, Neelima Chadha, Samir Malhotra
    Abstract:

    Background. Terminalia arjuna is a popular Indian medicinal plant with its bark been used for over centuries as cardiotonic. The bark has been found to contain several bioactive compounds including saponins and flavonoids. A number of experimental and clinical studies have been conducted to explore therapeutic potential of Terminalia arjuna in cardiovascular ailments specially in patients of coronary heart disease. A number of narrative reviews have been done but no systematic review has been conducted to date. Objective. To systematically review and conduct a meta-analysis on the available literature evaluating the efficacy of Terminalia arjuna in patients of chronic stable angina. Study selection. We included randomised, pseudo-randomized and before-after comparative studies which compared Terminalia arjuna/commercial preparation of Terminalia arjuna with current standard/ conventional treatment regimens in patients with chronic stable angina. Findings. Studies were found to be of poor methodological design. We found no significant difference in the Terminalia arjuna group as compared to control arm in the outcomes for which we were able to pool data and undertake meta-analysis. Conclusions. Currently, the evidence is insufficient to draw any definite conclusions in favour of or against Terminalia arjuna in patients of chronic stable angina. Further, well-controlled multicentric clinical trials need to be conducted in large number of patients to explore the therapeutic potential of Terminalia arjuna if any.

S K Maulik - One of the best experts on this subject based on the ideXlab platform.

  • beneficial effects of aqueous extract of stem bark of Terminalia arjuna roxb an ayurvedic drug in experimental pulmonary hypertension
    Journal of Ethnopharmacology, 2017
    Co-Authors: Himanshu Meghwani, Pankaj Prabhakar, Soheb Anwar Mohammed, Sandeep Seth, Milind P Hote, Sanjay K Banerjee, Sudheer Arava, Ruma Ray, S K Maulik
    Abstract:

    Abstract Ethnopharmacological relevance The stem bark of Terminalia arjuna (Roxb.) is widely used in Ayurveda in various cardiovascular diseases. Many animal and clinical studies have validated its anti-ischemic, antihypertensive, antihypertrophic and antioxidant effects. Pulmonary hypertension (PH) is a fatal disease which causes right ventricular hypertrophy and right heart failure. Pulmonary vascular smooth muscle hypertrophy and increased oxidative stress are major pathological features of PH. As available limited therapeutic options fail to reduce the mortality associated with PH, alternative areas of therapy are worth exploring for potential drugs, which might be beneficial in PH. Aim of the study The effect of a standardised aqueous extract of the stem bark of Terminalia arjuna (Roxb.) in preventing monocrotaline (MCT)-induced PH in rat was investigated. Materials and methods The study was approved by Institutional Animal Ethics Committe. Male Wistar rats (150–200 g) were randomly distributed into five groups; Control, MCT (50 mg/kg subcutaneously once), sildenafil (175 µg/kg/day three days after MCT for 25 days), and arjuna extract (TA125 and TA250 mg/kg/day orally after MCT for 25 days). PH was confirmed by right ventricular weight to left ventricular plus septum weight (Fulton index), right ventricular systolic pressure (RVSP), echocardiography, percentage medial wall thickness of pulmonary arteries (%MWT). Oxidative stress in lung was assessed by super oxide dismutase (SOD), catalase, reduced glutathione (GSH) and thiobarbituric acid reactive substance (TBARS). The protein expressions of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX-1) in lung and gene expression of Bcl2 and Bax in heart were analyzed by Western blot and RT PCR respectively. Results MCT caused right ventricular hypertrophy (0.58±0.05 vs 0.31±0.05; P arjuna and sildenafil. Conclusions Aqueous extract of Terminalia arjuna prevented MCT-induced pulmonary hypertension which may be attributed to its antioxidant as well as its effects on pulmonary arteriolar wall thickening.

  • Terminalia arjuna roxb protects rabbit heart against ischemic reperfusion injury role of antioxidant enzymes and heat shock protein
    Journal of Ethnopharmacology, 2005
    Co-Authors: K. Gauthaman, Sanjay K Banerjee, Amit K Dinda, C C Ghosh, S K Maulik
    Abstract:

    The bark of Terminalia arjuna Roxb. (TA) is widely recommended for the treatment of ischemic heart disease (IHD) in Indian system of medicine. Oral administration of TA for 12 weeks in rabbits caused augmentation of myocardial antioxidants; superoxide dismutase (SOD), catalase (CAT) and glutathione (GSH) along with induction of heat shock protein72 (HSP72). In vivo ischemic-reperfusion injury induced oxidative stress, tissue injury of heart and haemodynamic effects were prevented in the TA treated rabbit hearts. The study provides scientific basis for the putative therapeutic effect of TA in ischemic heart disease.

Sreeraj Gopi - One of the best experts on this subject based on the ideXlab platform.

  • medicinal properties of Terminalia arjuna roxb wight arn a review
    Journal of Traditional and Complementary Medicine, 2017
    Co-Authors: Augustine Amalraj, Sreeraj Gopi
    Abstract:

    Medicinal plants have been a main source of therapeutic agents from ancient time to cure diseases. Terminalia arjuna (Roxb.) Wight & Arn. (T. arjuna) is one of the most accepted and beneficial medicinal plants in indigenous system of medicine for the treatment of various critical diseases. This comprehensive review provides various aspects of its ethnomedical, phytochemical, pharmacognostical, pharmacological and clinical significance to different diseases particularly in cardiovascular conditions. This plant has a good safety outline when used in combination with other conventional drugs. This review highlights various medicinal properties of T. arjuna through different studies such as antioxidant, hypotensive, anti-atherogenic, anti-inflammatory, anti-carcinogenic, anti-mutagenic and gastro-productive effect.

Navjot Kaur - One of the best experts on this subject based on the ideXlab platform.

  • Terminalia arjuna in Chronic Stable Angina: Systematic Review and Meta-Analysis
    Cardiology Research and Practice, 2014
    Co-Authors: Navjot Kaur, Nusrat Shafiq, H. Negi, Avaneesh Pandey, Srinivas Reddy, Harpreet Kaur, Neelima Chadha, Samir Malhotra
    Abstract:

    Background. Terminalia arjuna is a popular Indian medicinal plant with its bark been used for over centuries as cardiotonic. The bark has been found to contain several bioactive compounds including saponins and flavonoids. A number of experimental and clinical studies have been conducted to explore therapeutic potential of Terminalia arjuna in cardiovascular ailments specially in patients of coronary heart disease. A number of narrative reviews have been done but no systematic review has been conducted to date. Objective. To systematically review and conduct a meta-analysis on the available literature evaluating the efficacy of Terminalia arjuna in patients of chronic stable angina. Study selection. We included randomised, pseudo-randomized and before-after comparative studies which compared Terminalia arjuna/commercial preparation of Terminalia arjuna with current standard/ conventional treatment regimens in patients with chronic stable angina. Findings. Studies were found to be of poor methodological design. We found no significant difference in the Terminalia arjuna group as compared to control arm in the outcomes for which we were able to pool data and undertake meta-analysis. Conclusions. Currently, the evidence is insufficient to draw any definite conclusions in favour of or against Terminalia arjuna in patients of chronic stable angina. Further, well-controlled multicentric clinical trials need to be conducted in large number of patients to explore the therapeutic potential of Terminalia arjuna if any.

Harpreet Kaur - One of the best experts on this subject based on the ideXlab platform.

  • Review Article Terminalia arjuna in Chronic Stable Angina: Systematic Review and Meta-Analysis
    2016
    Co-Authors: Harpreet Kaur, Neelima Chadha, Samir Malhotra
    Abstract:

    Copyright © 2014 Navjot Kaur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Terminalia arjuna is a popular Indian medicinal plant with its bark been used for over centuries as cardiotonic. The bark has been found to contain several bioactive compounds including saponins and flavonoids. A number of experimental and clinical studies have been conducted to explore therapeutic potential of Terminalia arjuna in cardiovascular ailments specially in patients of coronary heart disease. A number of narrative reviews have been done but no systematic review has been conducted to date. Objective. To systematically review and conduct a meta-analysis on the available literature evaluating the efficacy of Terminalia arjuna in patients of chronic stable angina. Study selection. We included randomised, pseudo-randomized and before-after comparative studies which compared Terminalia arjuna/commercial preparation of Terminalia arjunawith current standard/ conventional treatment regimens in patients with chronic stable angina. Findings. Studies were found to be of poor methodological design. We found no significant difference in the Terminalia arjuna group as compared to control arm in the outcomes for which we were able to pool data and undertake meta-analysis. Conclusions. Currently, the evidence is insufficient to draw any definit

  • Terminalia arjuna in Chronic Stable Angina: Systematic Review and Meta-Analysis
    Cardiology Research and Practice, 2014
    Co-Authors: Navjot Kaur, Nusrat Shafiq, H. Negi, Avaneesh Pandey, Srinivas Reddy, Harpreet Kaur, Neelima Chadha, Samir Malhotra
    Abstract:

    Background. Terminalia arjuna is a popular Indian medicinal plant with its bark been used for over centuries as cardiotonic. The bark has been found to contain several bioactive compounds including saponins and flavonoids. A number of experimental and clinical studies have been conducted to explore therapeutic potential of Terminalia arjuna in cardiovascular ailments specially in patients of coronary heart disease. A number of narrative reviews have been done but no systematic review has been conducted to date. Objective. To systematically review and conduct a meta-analysis on the available literature evaluating the efficacy of Terminalia arjuna in patients of chronic stable angina. Study selection. We included randomised, pseudo-randomized and before-after comparative studies which compared Terminalia arjuna/commercial preparation of Terminalia arjuna with current standard/ conventional treatment regimens in patients with chronic stable angina. Findings. Studies were found to be of poor methodological design. We found no significant difference in the Terminalia arjuna group as compared to control arm in the outcomes for which we were able to pool data and undertake meta-analysis. Conclusions. Currently, the evidence is insufficient to draw any definite conclusions in favour of or against Terminalia arjuna in patients of chronic stable angina. Further, well-controlled multicentric clinical trials need to be conducted in large number of patients to explore the therapeutic potential of Terminalia arjuna if any.